Louisiana v. FDA: mifepristone access, paused at the Supreme Court

On May 14, 2026, the Supreme Court stayed a Fifth Circuit order that would have eliminated mail and telehealth dispensing of mifepristone across the country. The Court’s action does not resolve the case. It preserves the current rules while the underlying litigation continues. But the gap between what the order does and what it decides is the part worth understanding.

What the Fifth Circuit held

The case is Louisiana v. FDA. It is the second major mifepristone challenge to reach the Supreme Court in three years, and it is built to avoid the defect that sank the first.

In 2024, in FDA v. Alliance for Hippocratic Medicine, the Court unanimously held that anti-abortion doctors and medical groups lacked standing to challenge the FDA’s expansion of mifepristone access. The plaintiffs there objected to the agency’s policy but could not show that the policy harmed them. Without a concrete injury, there was no case.

Louisiana — which bans nearly all abortion — filed its own suit in October 2025, advancing a different standing theory: that mifepristone mailed into the state causes abortions there in violation of Louisiana law, generates emergency-room visits, and imposes downstream costs the state must bear. The state paired that theory with a claim under the Administrative Procedure Act.

The APA is the statute that governs how federal agencies make rules. It lets courts set aside agency action found to be “arbitrary, capricious, or otherwise not in accordance with law.” Louisiana’s APA claim targets the FDA’s 2023 decision to formally remove mifepristone’s in-person dispensing requirement — the regulatory change, layered on a 2021 nonenforcement policy, that made mail and telehealth distribution possible. The state argued that decision was inadequately reasoned, pointing to the current HHS Secretary’s stated concern that the 2023 review gave insufficient weight to patient safety and to a pending FDA safety study that has not yet produced findings.

A federal district court declined to grant Louisiana interim relief. On May 1, 2026, a three-judge Fifth Circuit panel went the other way. It found Louisiana likely to succeed and used a specific procedural tool — Section 705 of the APA — to suspend the 2023 rule change while the appeal proceeds. The practical effect: the in-person dispensing requirement snapped back into force nationwide, immediately. Mifepristone could no longer be lawfully mailed or prescribed by telehealth in any state — including states where abortion is legal.

What the Supreme Court did

The two companies that manufacture mifepristone, Danco Laboratories and GenBioPro, filed emergency applications asking the Supreme Court to pause the Fifth Circuit’s order. Justice Alito, who handles emergency matters from the Fifth Circuit, first issued a short administrative stay, then extended it, while the Court considered the applications (SCOTUSblog).

On May 14, the Court granted the stay. Its order is brief and unsigned. It says the Fifth Circuit’s May 1 order “is stayed pending disposition of the appeal in the United States Court of Appeals for the Fifth Circuit and disposition of a petition for a writ of certiorari, if such a writ is timely sought” (Supreme Court order, No. 25A1207).

That sentence is the whole mechanism. A stay is not a ruling on the merits. It is a decision about which rules govern while the courts work — here, the FDA’s current rules, meaning mifepristone remains available by mail and telehealth. The Court gave no reasoning and disclosed no vote count, a pattern common to its emergency-docket orders. Standard stay doctrine asks whether the party seeking the pause faces irreparable harm and whether the balance of equities favors it; the majority’s silence leaves which factor proved decisive unstated.

Two justices dissented publicly. Justice Thomas wrote that the manufacturers should lose because shipping mifepristone for abortion violates the Comstock Act — a dormant 1873 anti-vice statute that bars mailing any “drug … for producing abortion” — and that a company “cannot, in any legally relevant sense, be irreparably harmed by a court order that makes it more difficult for them to commit crimes.” Justice Alito, in a longer dissent, called the majority’s “unreasoned order … remarkable” and framed the case as “the perpetration of a scheme to undermine our decision in Dobbs.” On the law, his objection was narrower: he argued the manufacturers had not shown irreparable injury, because a Section 705 suspension simply reverts mifepristone to its pre-2023 rules, “under which the manufacturers successfully operated for years.”

Where the case goes next

The stay sends the dispute back to the Fifth Circuit for full briefing and argument on the merits of Louisiana’s appeal. The stay holds until that appeal is resolved and, if a party then seeks Supreme Court review, until the Court disposes of that petition. If review is sought and denied, the stay dissolves automatically. If review is granted, it holds until the Court issues a decision.

In short: the May 14 order buys time, not closure. The threshold questions — whether Louisiana has standing under its downstream-cost theory, and whether the FDA’s 2023 rule survives APA review — remain open. The Comstock Act argument that Thomas pressed is not before the Court in this posture, but its appearance in a dissent signals it as live ground for future litigation.

What is at stake

The mechanism the case turns on is dry. The exposure is not.

Medication abortion — the mifepristone-and-misoprostol regimen — accounted for 63 percent of all US abortions in 2023, up from 53 percent in 2020, according to the Guttmacher Institute (Guttmacher Institute). It is now the majority method. Telehealth is a fast-growing share of that majority: roughly one in four clinician-provided abortions were delivered via telehealth by late 2024, with online-only clinics alone accounting for about 14 percent of abortions in states without total bans that year (Guttmacher Institute).

The Fifth Circuit’s order would have cut into both. Because the in-person dispensing requirement is a federal rule, suspending the 2023 change reaches every state — not only states with abortion bans. Patients in states where abortion is legal would have lost mail and telehealth access alongside everyone else. Mifepristone is also used to manage miscarriage, so the disruption would not have been confined to elective abortion care.

There is a structural point underneath the legal one. Alliance for Hippocratic Medicine turned away a challenge on standing; Louisiana v. FDA is an attempt to find a plaintiff — a state, asserting its own costs — who can clear that bar. The merits theory is an APA claim, the same category of administrative-law argument that drives much of current federal regulatory litigation: not a constitutional question, but a contention that an agency did not adequately justify a rule. The durability of mail-and-telehealth access now depends less on the Dobbs settlement of who decides abortion policy and more on how courts resolve a standing question and an arbitrary-and-capricious question. That is a narrower and more technical fight than the headline suggests — and, for the people who rely on the regimen, no less consequential.

What to watch

• The Fifth Circuit’s merits schedule. The appeal returns there for full briefing and argument; how fast the panel moves sets the timeline for everything downstream.
• The FDA’s safety review. The agency announced a study of the 2023 REMS and has taken no position in the litigation. Whether and how it acts could change the legal posture — and, by Alito’s own reasoning, the irreparable-harm calculus.
• The standing question. Whether Louisiana’s downstream-cost theory survives is the threshold issue. A ruling against it would echo Alliance for Hippocratic Medicine; a ruling for it would widen the class of plaintiffs who can challenge federal agency action.
• The Comstock Act. Raised in dissent, not decided. Its revival as an enforcement theory — by states or by a future administration — is a separate front from the APA case.
• State shield laws. The cross-border conflict between states that protect telehealth providers and states that prosecute them is unresolved and is being litigated on its own track.

The May 14 order keeps the status quo in place. It does not secure it. The questions that decide whether mail and telehealth dispensing survive have not been answered — only postponed.